On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Patentees and sponsors of New Drug Applications (NDAs ... which permits Teva to market and sell an inhaler device that administers the API albuterol sulfate. Teva listed several patents in ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.